Palmar plantar erythrodysesthesia pathophysiology: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "{{Palmar plantar erythrodysesthesia}} {{CMG}} ==Overview== '''Palmar plantar erythrodysesthesia''' (PPE) is a swelling and numbness of the hands and feet that occurs with [[ch...")
 
No edit summary
 
(38 intermediate revisions by 7 users not shown)
Line 1: Line 1:
__NOTOC__
{{Palmar plantar erythrodysesthesia}}
{{Palmar plantar erythrodysesthesia}}
{{CMG}}
{{CMG}}; {{AE}} {{MC}}
 
==Overview==
==Overview==
'''Palmar plantar erythrodysesthesia''' (PPE) is a swelling and numbness of the hands and feet that occurs with [[chemotherapy]], usually with [[fluorouracil]], [[capecitabine]], [[cytarabine]], and [[doxorubicin]].
The exact [[pathogenesis]] of palmar plantar erythrodysesthesia (PPE) is not completely understood. It is thought that PPE is caused by direct [[Toxicity|toxic]] effect of the [[Chemotherapeutic agents|chemotherapeutic drugs]] against [[Keratinocyte|keratinocytes]], [[excretion]] of the [[drugs]] in [[eccrine sweat glands]], or [[Type I hypersensitivity reaction|type I allergic reaction]]. The [[pathological]] features of PPE are non-specific. However, since PPE involves a [[Cytotoxicity|cytotoxic]] [[reaction]] primarily affecting [[Keratinocyte|keratinocytes]], the [[Histopathology|histopathologic]] findings are similar to [[Histology|histologic]] manifestation of direct [[Toxicity|toxic]] [[Reaction|reactions]].
 
==Pathophysiology==
==Pathophysiology==
The cause of PPE is unknown. Existing theories are based on the fact that only the hands and feet are involved and posit the role of temperature differences, vascular anatomy, differences in the types of cells (rapidly dividing epidermal cells and eccrine glands).
 
=== Pathogenesis ===
 
* The exact [[pathogenesis]] of palmar plantar erythrodysesthesia (PPE) is not completely understood.
* Suggested explanations include:
 
:* Direct [[Toxicity|toxic]] effect of the [[Chemotherapeutic agent|chemotherapeutic drugs]] against [[Keratinocyte|epidermal cells (keratinocytes)]].<ref>{{Cite journal
| author = [[J. E. Fitzpatrick]]
| title = The cutaneous histopathology of chemotherapeutic reactions
| journal = [[Journal of cutaneous pathology]]
| pmid = 8468414
}}</ref>
 
:*[[Concentration]] and [[excretion]] of [[Cytotoxicity|cytotoxic]] [[Drug|drugs]] in [[eccrine sweat glands]] causing damage or architectural insult.<ref name="pmid2061446">{{cite journal| author=Baack BR, Burgdorf WH| title=Chemotherapy-induced acral erythema. | journal=J Am Acad Dermatol | year= 1991 | volume= 24 | issue= 3 | pages= 457-61 | pmid=2061446 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2061446  }} </ref><ref>{{Cite journal
| author = [[Hiromi Tsuboi]], [[Kohzoh Yonemoto]] & [[Kensei Katsuoka]]
| title = A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature
| journal = [[The Journal of dermatology]]
| pmid = 16361756
}}</ref>
 
:* A [[Type 1 hypersensitivity|type I (immunoglobulin E [IgE]-mediated) allergic reaction]]. This explanation is based on the occasional co-occurrence of [[facial]] [[erythema]]/[[edema]], [[Papule|papular]] [[rash]], and [[fever]].<ref>{{cite book | last = Perry | first = Michael | title = Chemotherapy source book | publisher = Wolters Kluwer Health/Lippincott Williams & Wilkins | location = Philadelphia | year = 2012 | isbn = 9781451101454 }}</ref>
 
* Unique characteristics of the [[Palms of the hands|palms]] and the [[Sole (foot)|soles]] which justify their involvement as the preferred sites of involvement include:  <ref name="pmid2061446">{{cite journal| author=Baack BR, Burgdorf WH| title=Chemotherapy-induced acral erythema. | journal=J Am Acad Dermatol | year= 1991 | volume= 24 | issue= 3 | pages= 457-61 | pmid=2061446 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2061446  }} </ref> <ref>{{Cite journal
| author = [[W. S. Susser]], [[D. L. Whitaker-Worth]] & [[J. M. Grant-Kels]]
| title = Mucocutaneous reactions to chemotherapy
| journal = [[Journal of the American Academy of Dermatology]]
| pmid = 10071309
}}</ref> <ref>{{Cite journal
| author = [[Yvonne Lassere]] & [[Paulo Hoff]]
| title = Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)
| journal = [[European journal of oncology nursing : the official journal of European Oncology Nursing Society]]
| doi = 10.1016/j.ejon.2004.06.007
| pmid = 15341880
}}</ref>
 
:* High density of [[eccrine sweat glands]]<ref name="pmid2947543">{{cite journal| author=Cox GJ, Robertson DB| title=Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. | journal=Arch Dermatol | year= 1986 | volume= 122 | issue= 12 | pages= 1413-4 | pmid=2947543 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2947543  }} </ref>
 
:* Absence of [[Hair follicle|folliculo]]-[[Sebaceous gland|sebaceous]] units ([[Hair follicle|hair follicles]] and [[Sebaceous gland|sebaceous glands]])<ref name="pmid2947543">{{cite journal| author=Cox GJ, Robertson DB| title=Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. | journal=Arch Dermatol | year= 1986 | volume= 122 | issue= 12 | pages= 1413-4 | pmid=2947543 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2947543  }} </ref>
:* Thick [[stratum corneum]] <ref name="pmid2947543">{{cite journal| author=Cox GJ, Robertson DB| title=Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. | journal=Arch Dermatol | year= 1986 | volume= 122 | issue= 12 | pages= 1413-4 | pmid=2947543 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2947543  }} </ref>
:* Wide [[dermal papillae]] <ref name="pmid2947543">{{cite journal| author=Cox GJ, Robertson DB| title=Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. | journal=Arch Dermatol | year= 1986 | volume= 122 | issue= 12 | pages= 1413-4 | pmid=2947543 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2947543  }} </ref>
:* High [[Cell growth|proliferation]] rate of [[Epidermis (skin)|epidermal]] [[Basal cell|basal cells]]
:* The [[temperature]] and [[pressure gradient]]
:*[[Gravitation]] forces
:*[[Vascular]] [[anatomy]] peculiar to these areas
:* In cases caused by [[capecitabine]], higher [[expression]] of the [[capecitabine]]-activating [[enzyme]] [[thymidine phosphorylase]] in the [[skin]] of the [[Palms of the hands|palms]]<ref name="pmid3855356">{{cite journal| author=Levine LE, Medenica MM, Lorincz AL, Soltani K, Raab B, Ma A| title=Distinctive acral erythema occurring during therapy for severe myelogenous leukemia. | journal=Arch Dermatol | year= 1985 | volume= 121 | issue= 1 | pages= 102-4 | pmid=3855356 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3855356  }} </ref>
 
==Microscopic Pathology==
 
* The [[pathological]] features of PPE are non-specific.
* However, since PPE involves a [[Cytotoxicity|cytotoxic]] [[reaction]] primarily affecting [[Keratinocyte|keratinocytes]], the [[Histopathology|histopathologic]] findings are similar to [[Histology|histologic]] manifestation of direct [[Toxicity|toxic]] [[Reaction|reactions]]:
 
:* Dominantly an interface [[dermatitis]] with a [[Cell (biology)|cell]]-poor infiltrate
:* A variable degree of [[Epidermis (skin)|epidermal]] ([[Keratinocyte|keratinocytes]]) [[necrosis]]<ref name="pmid8468414">{{cite journal| author=Fitzpatrick JE| title=The cutaneous histopathology of chemotherapeutic reactions. | journal=J Cutan Pathol | year= 1993 | volume= 20 | issue= 1 | pages= 1-14 | pmid=8468414 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8468414  }} </ref>
 
* Generally, in mild [[Cytotoxicity|cytotoxic]] [[Reaction|reactions]] (PPE [[World Health Organization|WHO]] [[Grading (tumors)|grades]] 1 and 2), [[necrosis]] is restricted to [[Basal cell|basal keratinocytes]].
* In severe cytotoxic reactions ([[WHO|WHO grades]] 3 and 4) destruction of the entire [[Basal lamina|basal layer]] occurs, and a [[blister]] along with complete [[epidermal]] [[necrosis]] may also be seen.<ref name="pmid9643337">{{cite journal| author=Calista D, Landi C| title=Cytarabine-induced acral erythema: a localized form of toxic epidermal necrolysis? | journal=J Eur Acad Dermatol Venereol | year= 1998 | volume= 10 | issue= 3 | pages= 274-5 | pmid=9643337 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9643337  }} </ref>
 
* Other [[Histology|histologic]] manifestations in [[Epidermis (skin)|epidermis]] include:
:*[[Vacuole|Vacuolar]] degeneration of the [[Stratum basale|basal cell layer of epidermis]]
:* Mild [[Spongiosum|spongiosis]]
:*[[Hyperkeratosis]]
:* Lymphohistiocytic infiltrates
:*[[Apoptosis]] of [[keratinocytes]]
:* Partial separation of the [[epidermis]] from the [[dermis]]
 
*[[Dermal]] changes include:
 
:*[[Superficial]] perivascular [[Infiltration (medical)|infiltration]] of [[dermis]] by [[Lymphocyte|lymphocytes]] and [[eosinophils]]
:*[[Papillary]] [[dermal]] [[edema]]
:*[[Neutropenia|Neutrophilic]] [[Eccrine sweat glands|eccrine]] [[hidradenitis]]
:*[[Eccrine sweat glands|Eccrine]] [[squamous]] syringometaplasia, in severe PPE ([[WHO]] grades 3 and 4)
 
*[[Histological|Histologic]] evidence of small-[[Nerve fiber|fiber]] [[neuropathy]], as shown by reduced [[Epidermis (skin)|epidermal]] [[nerve fiber]] [[density]], has been suggested to be responsible for occurrence of [[neuropathic pain]], [[Dysesthesia|dysesthesias]], [[Paresthesia|paresthesias]], and [[temperature]] intolerance in PPE. <ref name="pmid19078798">{{cite journal| author=Stubblefield MD, Custodio CM, Kaufmann P, Dickler MN| title=Small-Fiber Neuropathy Associated with Capecitabine (Xeloda)-induced Hand-foot Syndrome: A Case Report. | journal=J Clin Neuromuscul Dis | year= 2006 | volume= 7 | issue= 3 | pages= 128-32 | pmid=19078798 | doi=10.1097/01.cnd.0000211401.19995.a2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19078798  }} </ref><br />
 
==References==
==References==
{{reflist|3}}
{{reflist|3}}
[[Category:Up-To-Date]]
[[Category:Oncology]]
[[Category:Medicine]]

Latest revision as of 19:35, 17 July 2019

Palmar plantar erythrodysesthesia Microchapters

Home

Overview

Historical perspective

Classification

Pathophysiology

Causes

Differentiating Palmar plantar erythrodysesthesia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Palmar plantar erythrodysesthesia pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Palmar plantar erythrodysesthesia pathophysiology

CDC on Palmar plantar erythrodysesthesia pathophysiology

Palmar plantar erythrodysesthesia pathophysiology in the news

Blogs on Palmar plantar erythrodysesthesia pathophysiology

Directions to Hospitals Treating Palmar plantar erythrodysesthesia

Risk calculators and risk factors for Palmar plantar erythrodysesthesia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]

Overview

The exact pathogenesis of palmar plantar erythrodysesthesia (PPE) is not completely understood. It is thought that PPE is caused by direct toxic effect of the chemotherapeutic drugs against keratinocytes, excretion of the drugs in eccrine sweat glands, or type I allergic reaction. The pathological features of PPE are non-specific. However, since PPE involves a cytotoxic reaction primarily affecting keratinocytes, the histopathologic findings are similar to histologic manifestation of direct toxic reactions.

Pathophysiology

Pathogenesis

  • The exact pathogenesis of palmar plantar erythrodysesthesia (PPE) is not completely understood.
  • Suggested explanations include:
  • Unique characteristics of the palms and the soles which justify their involvement as the preferred sites of involvement include: [2] [5] [6]

Microscopic Pathology

References

  1. ↑ J. E. Fitzpatrick. "The cutaneous histopathology of chemotherapeutic reactions". Journal of cutaneous pathology. PMID 8468414.
  2. ↑ 2.0 2.1 Baack BR, Burgdorf WH (1991). "Chemotherapy-induced acral erythema". J Am Acad Dermatol. 24 (3): 457–61. PMID 2061446.
  3. ↑ Hiromi Tsuboi, Kohzoh Yonemoto & Kensei Katsuoka. "A case of bleomycin-induced acral erythema (AE) with eccrine squamous syringometaplasia (ESS) and summary of reports of AE with ESS in the literature". The Journal of dermatology. PMID 16361756.
  4. ↑ Perry, Michael (2012). Chemotherapy source book. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. ISBN 9781451101454.
  5. ↑ W. S. Susser, D. L. Whitaker-Worth & J. M. Grant-Kels. "Mucocutaneous reactions to chemotherapy". Journal of the American Academy of Dermatology. PMID 10071309.
  6. ↑ Yvonne Lassere & Paulo Hoff. "Management of hand-foot syndrome in patients treated with capecitabine (Xeloda)". European journal of oncology nursing : the official journal of European Oncology Nursing Society. doi:10.1016/j.ejon.2004.06.007. PMID 15341880.
  7. ↑ 7.0 7.1 7.2 7.3 Cox GJ, Robertson DB (1986). "Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy". Arch Dermatol. 122 (12): 1413–4. PMID 2947543.
  8. ↑ Levine LE, Medenica MM, Lorincz AL, Soltani K, Raab B, Ma A (1985). "Distinctive acral erythema occurring during therapy for severe myelogenous leukemia". Arch Dermatol. 121 (1): 102–4. PMID 3855356.
  9. ↑ Fitzpatrick JE (1993). "The cutaneous histopathology of chemotherapeutic reactions". J Cutan Pathol. 20 (1): 1–14. PMID 8468414.
  10. ↑ Calista D, Landi C (1998). "Cytarabine-induced acral erythema: a localized form of toxic epidermal necrolysis?". J Eur Acad Dermatol Venereol. 10 (3): 274–5. PMID 9643337.
  11. ↑ Stubblefield MD, Custodio CM, Kaufmann P, Dickler MN (2006). "Small-Fiber Neuropathy Associated with Capecitabine (Xeloda)-induced Hand-foot Syndrome: A Case Report". J Clin Neuromuscul Dis. 7 (3): 128–32. doi:10.1097/01.cnd.0000211401.19995.a2. PMID 19078798.
Retrieved from "https://www.wikidoc.org/index.php?title=Palmar_plantar_erythrodysesthesia_pathophysiology&oldid=1576277"